- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06109883
LB-100 (PP2A Inhibitor) and Azenosertib (WEE1 Inhibitor) in Metastatic Colorectal Cancer Patients
Phase Ib Study With the Combination of LB-100 (PP2A Inhibitor) and Azenosertib (WEE1 Inhibitor) in Metastatic Colorectal Cancer Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The goal of this Phase Ib monocenter, open-label, non-randomized clinical trial is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of the combination of LB-100 and azenosertib in patients with metastatic colorectal cancer.
This study will consist of a dose escalation phase and a dose expansion phase. The dose escalation phase is designed to find the recommended phase II dose of LB-100 and azenosertib when given together. The dose expansion phase further explores the clinical activity, safety, tolerability and pharmacokinetics/dynamics of LB-100 and azenosertib.
Clinical assessments will be performed routinely to monitor safety. Anti-tumor activity will be measured by CT scan according to RECIST version 1.1 criteria. Tumor biopsies will be obtained for exploratory objectives.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Merel Lucassen, MD
- Phone Number: +31205129111
- Email: me.lucassen@nki.nl
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Signed Informed Consent Form (ICF);
- Age ≥ 18 years at time of signing ICF;
- Ability to comply with the study protocol;
- Histological or cytological confirmed colorectal cancer;
- Disease progression during treatment with standard of care;
- Measurable disease per Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST v1.1). Previously irradiated lesions can be considered as measurable disease only if progressive disease has been unequivocally documented at that site since radiation;
- Able and willing to undergo blood sampling and tumour biopsies at baseline, if no adequate archival material is available, and during therapy;
- Availability of representative tumor specimen for exploratory biomarker research;
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
- Life expectancy of at least 3 months;
Adequate hematologic and end-organ function as defined by:
- Absolute neutrophil (segmented and bands) count ≥1.0×109/L
- Platelets≥100×109/L
- Hemoglobin ≥5.6 mmol/L
- AST≤2.5×ULN
- ALT≤2.5×ULN
- Bilirubin ≤1.5×ULN
- Estimated glomerular filtration rate ≥50 mL/min by CKD-EPI
- Negative pregnancy test (urine or serum) for female patients with childbearing potential.
Exclusion Criteria:
- Unable to follow study procedures;
- Any current treatment with investigational drugs;
- Patients using prohibited medication;
- Any unresolved grade ≥ 2 toxicities related to prior treatments (excluding alopecia) according to CTCAE version 5.0;
- Participants with a clinically significant gastrointestinal disorder that in the opinion of the treating investigator could impact the absorption of azenosertib, including but not limited to refractory nausea and vomiting, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of azenosertib;
- Patients with galactosemia;
- History of another malignancy, except patients who have been disease free for at least 2 years, and/or patients with a history of completely resected non-melanoma skin cancer, and/or patients with indolent second malignancies, and/or patients with a history of low grade (Gleason score ≤6 = Grade Group 1) localized prostate cancer;
- Symptomatic or untreated leptomeningeal disease;
- Symptomatic or actively progressing central nervous system metastases. Patients with previously treated or untreated central nervous system metastases that are asymptomatic in the absence of corticosteroid and anti-convulsion therapy for at least 1 week are allowed to enrol. Brain metastasis must be stable, verified by imaging (e.g. brain MRI or CT);
- Patients with cardiac comorbidities: myocardial infarction within 6 months prior to in-clusion, heart failure New York Hart Association (NYHA) class III or higher or a stroke within 6 months prior to inclusion;
- Pregnant or breast-feeding (lactating) women;
- Patients with known alcoholism, drug addiction and/or psychiatric or physiological condition which in the opinion of the investigator would impair study compliance;
- Other severe, acute or chronic medical or psychological condition or laboratory ab-normality that may increase risk associated with study participation or study drug ad-ministration or that may interfere with the interpretation of study results in judgement of the investigator;
- Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: LB-100 plus azenosertib
LB-100 IV over 15 minutes on day 1 and day 3 in a 21 day cycle in escalating doses. Azenosertib orally once daily on day 1, 2, 3, 4, 5 followed by no administration on day 6 and 7, repeated three times in a 21 day cycle in escalating doses in the absence of disease progression or unacceptable toxicity |
Intravenously on day 1 and 3 every cycle at escalating doses
Other Names:
Orally on day 1-5 every week at escalating doses
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The recommended phase II dose of LB-100 and azenosertib
Time Frame: up to 2 years
|
up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease control rate
Time Frame: 6 months
|
Measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
|
6 months
|
Objective response rate
Time Frame: 6 months
|
Measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
|
6 months
|
Duration of overall response
Time Frame: up to 2 years
|
Measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
|
up to 2 years
|
Progression free survival
Time Frame: up to 2 years
|
Measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
|
up to 2 years
|
Overall survival
Time Frame: Assessed up to 2 years
|
The time from the first dose of study treatment to the time of death from any cause.
Patients who are still alive at the time of analysis will be censored at the time of their last study assessment (for active patients) or at the last date know alive (for patients in follow-up).
|
Assessed up to 2 years
|
The incidence and severity of adverse events
Time Frame: Up to 2 years
|
As assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
|
Up to 2 years
|
The incidence of dose-limiting toxicity
Time Frame: 21 days
|
As assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
|
21 days
|
Observed plasma concentrations of LB-100, its active metabolite endothall and azenosertib
Time Frame: Prior to initial dose and the first cycle on day 1 and 2. Each cycle is 21 days
|
Blood samples are obtained and plasma concentrations of LB-100, endothall and azenosertib are measured
|
Prior to initial dose and the first cycle on day 1 and 2. Each cycle is 21 days
|
Area under the plasma-time concentration curve of LB-100, its active metabolite endothall and azenosertib
Time Frame: Prior to initial dose and the first cycle on day 1 and 2. Each cycle is 21 days
|
Blood samples are obtained and plasma concentrations of LB-100, endothall and azenosertib are measured
|
Prior to initial dose and the first cycle on day 1 and 2. Each cycle is 21 days
|
Elimination half-life of LB-100, its active metabolite endothall and azenosertib
Time Frame: Prior to initial dose and the first cycle on day 1 and 2. Each cycle is 21 days
|
Blood samples are obtained and plasma concentrations of LB-100, endothall and azenosertib are measured
|
Prior to initial dose and the first cycle on day 1 and 2. Each cycle is 21 days
|
Total body clearance of LB-100, its active metabolite endothall and azenosertib
Time Frame: Prior to initial dose and the first cycle on day 1 and 2. Each cycle is 21 days
|
Blood samples are obtained and plasma concentrations of LB-100, endothall and azenosertib are measured
|
Prior to initial dose and the first cycle on day 1 and 2. Each cycle is 21 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Neeltje Steeghs, MD, PhD, The Netherlands Cancer Institute - Antoni van Leeuwenhoek
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- LB100
Other Study ID Numbers
- N23LAC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Colorectal Cancer
-
Mayo ClinicCompletedMetastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Metastatic... and other conditionsUnited States
-
Emory UniversityBristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of...Active, not recruitingColorectal Cancer Metastatic | Colorectal Adenocarcinoma | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Refractory Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal Carcinoma | Stage IVC Colorectal CancerUnited States
-
Hutchison Medipharma LimitedActive, not recruitingMetastatic Colorectal Cancer | Metastatic Colon CancerUnited States, Spain, Japan, Australia, Austria, Belgium, Czechia, Estonia, France, Germany, Hungary, Italy, Poland, United Kingdom
-
Array Biopharma, now a wholly owned subsidiary...CompletedMetastatic Colorectal Cancer | Advanced Solid Tumors | Advanced or Metastatic Biliary CancerUnited States
-
Zhejiang Cancer HospitalNot yet recruitingMetastatic Colorectal Cancer | Metastatic Colorectal Adenocarcinoma | CRCChina
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Gastroesophageal Junction Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Malignant... and other conditionsUnited States
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer
-
Dana-Farber Cancer InstituteAmerican Cancer Society, Inc.Not yet recruitingMetastatic Colorectal Cancer | Colorectal Cancer | Metastatic Colon CancerUnited States
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer | Oncology
-
Symphogen A/STerminatedCarcinoma | Metastatic Colorectal Cancer | Colorectal Cancer MetastaticUnited States, Spain, Germany, Italy
Clinical Trials on LB-100
-
The Netherlands Cancer InstituteNot yet recruitingMetastatic Microsatellite-stable Colorectal Cancer
-
LISCure BiosciencesCompletedRheumatoid Arthritis | Non-Alcoholic SteatohepatitisAustralia
-
National Cancer Institute (NCI)CompletedGlioma | Glioblastoma Multiforme | Giant Cell Glioblastoma | Oligodendrogliomas | Astrocytoma, Grades II, III and IVUnited States
-
Lixte Biotechnology Holdings, Inc.UnknownMyelodysplastic SyndromesUnited States
-
LG ChemNot yet recruitingUrothelial Carcinoma | Malignant Melanoma | Non-small Cell Lung Cancer(NSCLC) | Head and Neck Squamous Cell Carcinoma(HNSCC) | Renal Cell Carcinoma(RCC)
-
M.D. Anderson Cancer CenterGSK Pharma; LixteRecruitingOvarian Clear Cell CarcinomaUnited States
-
Inova Health Care ServicesMedtronicRecruitingLeft Bundle-Branch Block | Heart Failure (HF) | Left Ventricular Ejection FractionUnited States
-
University of California, San DiegoCalifornia Institute for Regenerative Medicine (CIRM); Cystinosis Research...Active, not recruiting
-
Lixte Biotechnology Holdings, Inc.Completed
-
Grupo Espanol de Investigacion en SarcomasRecruitingAdvanced Soft-tissue SarcomaSpain